Appeal No. 94-4129
Application 07/953,439
Due to the long duration of action, galanthamine,
which incorporates the properties of physostigmine
and neostigmine, is a valuable agent in anesthesiology,
since many patients suffer from a central anticholinergic
syndrome after a general anaesthesia (Cozanitis, . . .
Anaesthesist 26, 649-650 (1977).
The claims on appeal are directed to a transdermal
applicator comprising (a) an impermeable backing layer, (b) a
polymer matrix which contains galanthamine and is connected to
the backing layer, and (c) a pressure-sensitive adhesive
element for affixation to the skin. Claim 16, which is
representative of the claimed subject matter, is reproduced in
the attached Appendix.
We hereby cite for the first time Hille et al. (Hille
II),
U.S. 5,700,480, patented December 23, 1997 (copy attached),
which issued from Application 08/495,609, filed September 29,
1995. Hille II and this application appear to be commonly
assigned to LTS Lohman Therapie-Systeme GmbH & Co. KG. Hille
II claims a transdermal therapeutic system for therapeutic
administration of galanthamine comprising (a) an impermeable
backing layer, (b) a polyacrylate reservoir which contains
galanthamine and is connected to the backing layer, and (c) a
pressure-sensitive adhesive element for affixation to the
- 4 -
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Next
Last modified: November 3, 2007